Following a rigorous review and data synthesis, the panel agreed on seven treatment recommendations. They note that in their recommendations, the word "recommend" indicates strong recommendations, and the word "suggest" indicates conditional recommendations.
@drsamiarashid

In their recommendations about drugs, the guideline panel used the word "only" when there was "higher uncertainty and/or more potential for harm."

They also used the phrase "knowledge gap" to accentuate their statements on the seven recommendations.

1) Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends hydroxychloroquine/chloroquine in the context of a clinical trial. (Knowledge gap)

2)Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends hydroxychloroquine/chloroquine plus azithromycin only in the context of a clinical trial. (Knowledge gap)

3) Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends the combination of lopinavir/ritonavir only in the context of a clinical trial. (Knowledge gap)

4) Among patients who have been admitted to the hospital with COVID-19 pneumonia, the IDSA guideline panel suggests not using corticosteroids. (Knowledge gap)

5) Among patients who have been admitted to the hospital with acute respiratory distress syndrome associated with COVID-19, the IDSA guideline panel recommends the use of corticosteroids in the context of a clinical trial. (Knowledge gap)

6)Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends tocilizumab only in the context of a clinical trial. (Knowledge gap)

7) Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends COVID-19 convalescent plasma in the context of a clinical trial. (Knowledge gap)

The document also includes "narrative summaries" of other treatments currently undergoing evaluation and for which more data are needed to formulate recommendations.

These treatments are the following: HIV antivirals, lopinavir-ritonavir combined with interferon beta or other antivirals; COVID-19 convalescent plasma for prophylaxis; ribavirin; oseltamivir; intravenous immunoglobulin; remdesivir; stopping nonsteroidal anti-inflammatory drugs

angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy for COVID-19 patients.

#Kashmir @principalgmcsgr @diprjk @drsamiarashid